Milestone Pharmaceuticals (MIST) said Friday the US Food and Drug Administration has accepted for review its response to issues raised in the regulator's complete response letter for Cardamyst nasal spray.
The FDA has set a target action date of Dec. 13.
Cardamyst nasal spray is a novel investigational therapy for the treatment of acute episodes of paroxysmal supraventricular tachycardia, a type of abnormal heart rhythm.
Shares of the company were down ore than 24% in Friday premarket activity.
Price: 1.94, Change: -0.62, Percent Change: -24.22
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.